Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.

Ermer JC, Pennick M, Frick G.

Clin Drug Investig. 2016 May;36(5):341-56. doi: 10.1007/s40261-015-0354-y. Review.

2.
4.

A review of psychostimulant-induced neuroadaptation in developing animals.

Carrey N, Wilkinson M.

Neurosci Bull. 2011 Jun;27(3):197-214. doi: 10.1007/s12264-011-1004-x. Review.

5.

Lisdexamfetamine dimesylate: the first prodrug stimulant.

Goodman DW.

Psychiatry (Edgmont). 2007 Aug;4(8):39-45.

7.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Froehlich TE, McGough JJ, Stein MA.

CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review.

8.

Long-acting stimulants: development and dosing.

Swanson JM.

Can Child Adolesc Psychiatr Rev. 2005 Aug;14(Supplement 1):4-9. No abstract available.

9.

Abuse of amphetamines and structural abnormalities in the brain.

Berman S, O'Neill J, Fears S, Bartzokis G, London ED.

Ann N Y Acad Sci. 2008 Oct;1141:195-220. doi: 10.1196/annals.1441.031. Review.

10.

Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Berman SM, Kuczenski R, McCracken JT, London ED.

Mol Psychiatry. 2009 Feb;14(2):123-42. doi: 10.1038/mp.2008.90. Epub 2008 Aug 12. Review. Erratum in: Mol Psychiatry. 2010 Nov;15(11):1121.

11.

Pharmacologic mechanisms of crystal meth.

Kish SJ.

CMAJ. 2008 Jun 17;178(13):1679-82. doi: 10.1503/cmaj.071675. Review.

12.

The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.

Stein MA, McGough JJ.

Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):475-90, xi-xii. doi: 10.1016/j.chc.2007.11.009. Review.

Supplemental Content

Support Center